Bactiguard Holding AB (Publ): Changes to the Nomination Committee Appointed for the Annual General Meeting 2016

Regulatory News:

Attorney Jan Lombach will replace Christian Kinch and has also been appointed chairman of the Nomination Committee.

Following these changes, the Nomination Committee for the 2016 AGM in Bactiguard Holding AB (publ) (STO:BACTIB) will consists of the following members:

Stanley Brodén, Chairman of the Board of Directors

Jan Lombach, appointed by KK Invest AB, Chairman of the Nomination Committee

Michael Wigge, appointed by Bactiguard B.V.

Christian Brunlid, appointed by Handelsbanken Fonder AB

The Nomination Committee will make proposals to the AGM 2016 concerning the election of a Chairman for the AGM, the Chairman and other members of the Board of Directors, as well as auditors. The Nomination Committee will also make proposals regarding remuneration to the Board of Directors, including any separate remuneration for committee work, as well as remuneration to the auditors. Further, the Nomination Committee will make a proposal regarding principles for forming the Nomination Committee for the AGM in 2017.

Shareholders who wish to make proposals to the Nomination Committee can do so by writing to the Nomination Committee under the following address:

Nomination Committee

Bactiguard Holding AB (publ)

Box 15

146 21 Tullinge

Proposals can also be sent by email to the following address: valberedningen@bactiguard.se

In order for the Nomination Committee to be able to address proposals in a constructive manner, they should have been received by January 15, 2016.

The proposals of the Nomination Committee will be presented in the invitation to the AGM and at the company’s website.

About Bactiguard

Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, Latin America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters is located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20151209006641/en/